Lazertinib

Lazertinib

Chemical structure of Lazertinib

Lazertinib is a tyrosine kinase inhibitor (TKI) used in the treatment of certain types of non-small cell lung cancer (NSCLC). It specifically targets the epidermal growth factor receptor (EGFR) mutations that are often implicated in the development and progression of NSCLC. Lazertinib is designed to overcome resistance to earlier generations of EGFR inhibitors, particularly those that develop due to the T790M mutation.

Mechanism of Action

Lazertinib works by selectively inhibiting the activity of mutant forms of the EGFR, which are known to drive the growth of cancer cells in NSCLC. By binding to the ATP-binding site of the EGFR, lazertinib prevents the receptor from activating downstream signaling pathways that promote cell proliferation and survival. This inhibition is particularly effective against the T790M mutation, a common resistance mechanism to first- and second-generation EGFR inhibitors.

Clinical Use

Lazertinib is primarily used in patients with advanced or metastatic NSCLC who have specific EGFR mutations. It is often prescribed after the failure of first-line EGFR TKIs due to resistance mutations. The drug has shown efficacy in shrinking tumors and delaying disease progression in clinical trials.

Development and Approval

Lazertinib was developed by Yuhan Corporation, a South Korean pharmaceutical company. It has undergone various phases of clinical trials to establish its safety and efficacy. The drug has been approved for use in several countries, with ongoing studies to further explore its potential in combination therapies and in earlier lines of treatment.

Side Effects

Common side effects of lazertinib include rash, diarrhea, and fatigue. These are generally manageable with supportive care. More serious adverse effects can include interstitial lung disease and liver enzyme abnormalities, which require careful monitoring and management.

Related Pages

• Epidermal growth factor receptor
• Non-small cell lung cancer
• Tyrosine kinase inhibitor
• Cancer treatment